1. Home
  2. AIOT vs GYRE Comparison

AIOT vs GYRE Comparison

Compare AIOT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PowerFleet Inc.

AIOT

PowerFleet Inc.

HOLD

Current Price

$5.61

Market Cap

665.1M

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.49

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIOT
GYRE
Founded
1993
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
665.1M
755.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIOT
GYRE
Price
$5.61
$7.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$10.50
$17.00
AVG Volume (30 Days)
1.1M
106.1K
Earning Date
02-09-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$425,867,000.00
$107,265,000.00
Revenue This Year
$23.71
$11.59
Revenue Next Year
$9.22
$26.31
P/E Ratio
N/A
$193.40
Revenue Growth
92.93
2.13
52 Week Low
$3.70
$6.11
52 Week High
$8.71
$13.75

Technical Indicators

Market Signals
Indicator
AIOT
GYRE
Relative Strength Index (RSI) 60.78 51.18
Support Level $5.38 $6.83
Resistance Level $5.63 $7.71
Average True Range (ATR) 0.19 0.35
MACD 0.01 0.05
Stochastic Oscillator 87.96 57.63

Price Performance

Historical Comparison
AIOT
GYRE

About AIOT PowerFleet Inc.

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: